Sign In
Buy ORGO
$2.33
+0.0900 (+4.02%)
At Close: Jun 03, 2026
Organogenesis Q1 Earnings Call Highlights
04:07pm, Friday, 08'th May 2026
Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following Medi
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
05:21am, Friday, 08'th May 2026
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the dev
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
04:30pm, Tuesday, 28'th Apr 2026
If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain
What's Going On With Organogenesis Stock On Wednesday?
10:15am, Wednesday, 08'th Apr 2026
Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight
01:01pm, Tuesday, 07'th Apr 2026
Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant re
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
08:22am, Tuesday, 07'th Apr 2026
The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
07:02pm, Monday, 06'th Apr 2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of p
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
05:30pm, Monday, 06'th Apr 2026
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leadin
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
07:30am, Monday, 06'th Apr 2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the d
SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO
04:59am, Saturday, 04'th Apr 2026
SG Americas Securities LLC raised its holdings in Organogenesis (NASDAQ: ORGO) by 199.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The firm own
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
11:57pm, Thursday, 26'th Feb 2026
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
04:05pm, Thursday, 26'th Feb 2026
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
04:05pm, Thursday, 19'th Feb 2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
02:05pm, Tuesday, 03'rd Feb 2026
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or the “Company”) (NASDAQ: ORGO). Such
